human tetanus immunoglobulin

Human Tetanus Immunoglobulin (HTIG) is a biologic therapy consisting of pre-formed antibodies (IgG) derived from the plasma of human donors who have high titers of antibody to the tetanus toxin. It provides immediate passive immunization by binding to and neutralizing the tetanospasmin exotoxin produced by *Clostridium tetani*, thereby preventing the toxin from binding to nerve synapses and causing the clinical symptoms of tetanus. In the context of clinical development by Sinovac Life Sciences, HTIG is utilized as an active comparator in Phase I/II trials (such as the SNA02-48 study) to evaluate the safety, pharmacokinetics, and pharmacodynamics of novel anti-tetanus monoclonal antibodies. HTIG is an established medical product used for post-exposure prophylaxis in individuals with tetanus-prone wounds who have an uncertain or incomplete immunization history, providing protection for approximately 3 to 4 weeks.

Brand names

SUYA-HT

Other names

Human Tetanus ImmunoglobulinTetanus Immune GlobulinHTIG-Sinovac Life Sciences Co., Ltd.-tetanus